C4x Discovery Share Discussion Threads

[parob] 08/3/2019 17:08

The share price has to turn at some point. Market Cap is looking ridiculously cheap. The odd few pennies here or there will make hardly any difference when the next licensing deal is announced or the next payment from Invidior is RNSed. These are shares to tuck away and be patient.If it drops lower I'll average down too. Paid off at EML, when they dropped to 2.4p and no one else was interested.

[richardjohn10] 08/3/2019 16:46

Yeah hopefullyAverage as low as possible

[john henry] 08/3/2019 16:45

Then watch the share price sink lower and lower Richard.

[john henry] 08/3/2019 16:42

AIM all share down 0.5% today C4XD down 5.3%

TT dont forget theres very few buyers.

Company needs to start doing what it promised.

[richardjohn10] 08/3/2019 16:41

Agreed TT I'll keep addingNo brainer

[trotterstrading] 08/3/2019 16:38

Traders selling out after realising they will need to hold for more than a few days ;0) general weakness across the market is not helping

[john henry] 08/3/2019 16:31

All time EOD low. O Dear not what the script book said last April.

Technicals show a simple bounce from an oversold position, target 48p.

Even before CF hit the scene, PA was trending steeply down, CF dumping stock just accelerated the trend down.

Trend is still firmly down.

[john henry] 08/3/2019 16:14

Market doesnt want sellers, tiny sells collapsing the bid.

Looks set for new all time lows. Traders that entered thinking CF was out got things wrong.

CEO buys gave a very temporary lift. Mind u he only bought a hand full.

[rafboy] 08/3/2019 16:13

Should have waited a bit longer to top up LOL.

[trotterstrading] 08/3/2019 15:28

Nice but if volume to clear out the sellers, then we can move up

[rafboy] 08/3/2019 11:19

Had a small top up this morning. Pleased to have bought below recent director buy.

[trotterstrading] 08/3/2019 08:01

Fair play Dave, all healthy debate

[trotterstrading] 07/3/2019 18:29

Dave with respect Clive is in a different league to 99% of AIM CEO's, and when you man with his track record says the following you have to sit up and take note "Having seen from an executive position the potential of the platform to generate entirely new compounds against high-value therapeutic targets more rapidly and efficiently than any technology I've come across before and having witnessed the interest we're receiving in C4X Discovery, I am delighted to take the helm on a full-time basis. I have never been more excited by a company than this one."Dr Dix is widely recognised as one of the leading figures in the UK biotechnology sector, combining track records as a serially successful entrepreneur and an experienced pharmaceutical R&D executive. Most recently, Dr Dix was CEO of Convergence Pharmaceuticals, which was sold to Biogen in January 2015 for $675m. Prior to that, Dr Dix enjoyed successful exits with PowderMed Limited, Auralis Limited and PowderJect Pharmaceuticals plc, where he held the roles of CEO, Chairman and Head of R&D, respectively. Before his move into biotechnology, Dr Dix was UK Research Director for GlaxoWellcome. He currently serves as Chairman of Touchlight Genetics Ltd and Centauri Therapeutics Ltd, and was Chairman of the UK BioIndustry Association (BIA) from 2008-2010.

[davemac3] 07/3/2019 18:21

I think to claim best in class they would have to make all the competitor molecules (assuming they know the structures) and profile them against their own for each target.

[trotterstrading] 07/3/2019 17:43

Dave, it's on their website 11 discovery programs, up from 9 a few months ago. Worth noting that to be added to the program pipeline means they have identified a molecule which has activity against a specific disease pathway. They are using cutting edge big data analysis coupled with the latest 3D and virtual reality technology to identify what they call best in class molecules

[davemac3] 07/3/2019 17:19

where have they claimed to have 11 best in class molecules? that seems to be pushing it a bit!

[richardjohn10] 07/3/2019 16:36

Very happy accumulating here nice and quietly.

[trotterstrading] 07/3/2019 16:29

32m Mcap for a cutting edge Biotech with c.£12m in the bank, a $300m license deal in their back pocket and pipeline of 11 best in class molecules, 2 at license stage! Oh and a FTSE Calibre Mgmt team with a proven track record of value creation.. lol, the madness of AIM

[richardjohn10] 07/3/2019 14:45

This is a gift imo and limited downside. Investors dream

[trotterstrading] 07/3/2019 13:19

Clear then out, this is not a traders share tbh, not liquid enough. Serious Mgmt team here that have zero interest in AIM shenanigans required to inflate the share price Sit tight wait a month or two and I think you will make serious money

[john henry] 07/3/2019 13:12

Traders now dumping stock and crashing the price on next to no liquidity

[john henry] 07/3/2019 12:40

Recent selling has turned sentiment negative, hopefully a turn around soon from all time lows Would appear the MMs are still awash with stock.